Suppr超能文献

抗布鲁氏菌疫苗的控制方法及可接受性阈值

Control methods and thresholds of acceptability for antibrucella vaccines.

作者信息

Bosseray N

机构信息

Institut National de la Recherche Agronomique Laboratoire de Pathologie Infectieuse et Immunologie, INRA, Nouzilly, France.

出版信息

Dev Biol Stand. 1992;79:121-8.

PMID:1286747
Abstract

Protection against brucellosis involves both cellular and humoral effectors not yet fully appreciated. Living or killed vaccines can protect against the infection itself or only against abortion. For official controls, vaccines (or new procedures of vaccination) must first be characterized pharmacologically and tested for innocuity. Protection must be tested on natural hosts with a reference vaccine (S19 or Rev. 1) by the agreed method which reproduces the natural infection and measures immunity in toto. Control and vaccinated females are challenged by the conjunctival route at mid-pregnancy under standard conditions (strain, dose) to measure the resulting infection by bacteriological analysis of excretion at parturition and of infection in target organs at slaughter. Results are principally expressed by the infection rate which should be +/- 95% in the control group. In the new vaccine group the rate should be equivalent to, or lower than, the reference vaccine group. To be statistically valid, at least 30 animals per group are required. For routine controls, laboratory models using guinea pigs, not well standardized, inaccurate and expensive, have long been proposed. The mouse model, extensively studied and standardized, should now be preferred to the guinea pig model. In the mouse model, residual virulence of a living vaccine is estimated by the time required by 50% of the mice to eradicate the strain from their spleen (Recovery Time 50%). Immunogenicity is measured by the ability of mice to restrict their splenic infection after a virulent i.p. challenge at a dose (B. abortus 544; 2 x 10(5) cfu) chosen in order that all mice were still infected 15 days post challenge.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

针对布鲁氏菌病的防护涉及细胞和体液效应因子,但其尚未得到充分认识。活疫苗或灭活疫苗可预防感染本身或仅预防流产。对于官方管控而言,疫苗(或新的疫苗接种程序)必须首先进行药理学特性鉴定并检测其无害性。必须通过公认的方法,使用参考疫苗(S19或Rev. 1)在天然宿主上测试防护效果,该方法可重现自然感染并全面衡量免疫力。在标准条件(菌株、剂量)下,对处于妊娠中期的对照雌性和接种疫苗的雌性通过结膜途径进行攻毒,以通过对分娩时排泄物和屠宰时靶器官感染情况进行细菌学分析来测定由此产生的感染。结果主要以感染率表示,对照组的感染率应为±95%。在新疫苗组中,该比率应等于或低于参考疫苗组。为使统计有效,每组至少需要30只动物。长期以来,一直有人提议使用未充分标准化、不准确且昂贵的豚鼠实验室模型进行常规管控。现在,经过广泛研究和标准化的小鼠模型应优先于豚鼠模型。在小鼠模型中,活疫苗的残余毒力通过50%的小鼠从脾脏中清除该菌株所需的时间(恢复时间50%)来估算。免疫原性通过小鼠在腹腔注射毒力菌株(流产布鲁氏菌544;2×10⁵ cfu)攻毒后限制脾脏感染的能力来衡量,选择该剂量是为了使所有小鼠在攻毒后15天仍被感染。(摘要截取自250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验